Skip to main content

Once Daily In-Situ Forming Versus Twice-Daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis: A Randomized Controlled Trial

Research Authors
Shabaan O.M., Abbas A.M., Fetih G.N., Abdellah N.H., Ibrahim E.A., Nasr A.M., Badran S.M. and Abdullah S.A.
Research Department
Research Journal
J. Genit. Syst. Disor., doi:10.4172/2325-9728.1000138
Research Publisher
NULL
Research Rank
1
Research Vol
Vol. 4, No. 3
Research Website
http://dx.doi.org/10.4172/2325-9728.1000138
Research Year
2015
Research Member
Research Abstract

Background: Bacterial vaginosis (BV) is one of the most common infections in childbearing age.
Aim: To compare the efficacy of metronidazole (once-daily 0.8% MTZ in situ gel) versus twice-daily conventional MTZ vaginal gel in the treatment of bacterial vaginosis (BV).
Material and methods: All patients who presented to Assiut Women Health Hospital- Egypt with symptoms suggestive of BV were counseled to participate in the study. One hundred-four eligible participants were randomly assigned to either MTZ in situ gel or a conventional vaginal gel. All participants were followed-up twice after one and 4 weeks of the beginning of treatment to ensure cure of infection and any side-effects.
Results: Demographic criteria of the participants were matched in both groups. The cure rate after one week from the treatment was 74.5% in the in situ gel group and 63.8% in the conventional vaginal gel group (P=0.252), while after 4 weeks, the cure rate showed significant difference in the in situ gel group as compared to the conventional vaginal gel group (66.7%) and (40.4%), respectively (P=0.009).
Conclusion: Once daily in situ MTZ gel (0.8%) is more effective than twice-daily conventional gel after four weeks of treatment with nearly same side effects. These findings confirm the use of this novel and efficient modality of long-term treatment of BV.